Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells

Wei,Changran; Li,Xiangqi

doi:10.3892/mmr.2020.11482

Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells

Authors:
- Changran Wei
- Xiangqi Li
View Affiliations

Affiliations: Department of The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China
Published online on: September 2, 2020 https://doi.org/10.3892/mmr.2020.11482
Pages: 3955-3961
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most aggressive malignant tumors in women. According to the expression differences of estrogen receptor, progesterone receptor, human epidermal growth factor receptor‑2 (HER‑2) and cell proliferation antigen Ki‑67, breast cancer can be divided into four molecular subtypes: Luminal A, Luminal B, HER‑2 overexpression and Basal‑like. Yes‑associated protein (YAP), a downstream effector of the Hippo pathway, is overexpressed in human cancers and is associated with proliferation, apoptosis, migration, invasion and resistance to chemotherapy drugs in breast cancer cells. Verteporfin (VP) is used as a photosensitizer in the treatment of neovascular macular degeneration. VP is also identified as an inhibitor of YAP/TEA domain transcription factor (TEAD) interaction in the absence of light activation. However, detailed structural information about VP and YAP interactions is relatively scarce and VP research targeting YAP in different molecular subtypes of breast cancer cells is also rare. The aims of the present study were to structurally describe the VP binding site in the YAP crystal structure and to verify the non‑photoreactive VP effect targeting YAP on the migration of different molecular subtypes of breast cancer cells. The crystal structure of VP and YAP was calculated by AutoDock 4.2 and the result was illustrated using PyMOL. The non‑photoactivated VP effect on the migration of Luminal A MCF‑7, Luminal B BT‑474 and triple‑negative breast cancer BT‑549 breast cancer cells was evaluated by wound healing and Transwell migration experiments. Results from molecular docking experiments demonstrated that VP could interact through hydrogen bonds and hydrophobic interactions with important YAP residues involved in TEADs binding (Gln82, Val84, Met86 and Arg89). Migration experiments revealed that the non‑photoinduced VP could inhibit the migration of different molecular subtypes of breast cancer cells. The results of the present study indicated that VP may be a novel repositioned drug for breast cancer treatment in the future.

View Figures

View References

1	Fu V, Plouffe SW and Guan KL: The Hippo pathway in organ development, homeostasis, and regeneration. Curr Opin Cell Biol. 49:99–107. 2017. View Article : Google Scholar : PubMed/NCBI
2	Holden JK and Cunningham CN: Targeting the hippo pathway and cancer through the TEAD family of transcription factors. Cancers (Basel). 10:812018. View Article : Google Scholar
3	Xie D, Nakachi K, Wang H, Elashoff R and Koeffler HP: Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 61:8917–8923. 2001.PubMed/NCBI
4	Luo XL, Yan Q, Tao DD, Hu JB, Li ZM, Li XL and Gong JP: Effects of MST1 on cell proliferation and apoptosis of human carcinoma cell line MCF-7. Tumor. 28:852–854. 2008.
5	Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA and Pan D: A temporal requirement for Hippo signalling in mammary gland differentiation, growth and tumorigenesis. Genes Dev. 28:432–437. 2014. View Article : Google Scholar : PubMed/NCBI
6	Heidary Arash E, Shiban A, Song S and Attisano L: MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep. 18:420–436. 2017. View Article : Google Scholar : PubMed/NCBI
7	Scott LJ and Goa KL: Verteporfin. Drugs Aging. 16:139–146; discussion 147–148. 2000. View Article : Google Scholar : PubMed/NCBI
8	Richter AM, Waterfield E, Jain AK, Allison B, Sternberg ED, Dolphin D and Levy JG: Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer. 63:87–93. 1991. View Article : Google Scholar : PubMed/NCBI
9	Ziemssen F and Heimann H: Evaluation of verteporfin pharmakokinetics-redefining the need of photosensitizers in ophthalmology. Expert Opin Drug Metab Toxicol. 8:1023–1041. 2012. View Article : Google Scholar : PubMed/NCBI
10	Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D: Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26:1300–1305. 2012. View Article : Google Scholar : PubMed/NCBI
11	Plouffe SW, Hong AW and Guan KL: Disease implications of the Hippo/YAP pathway. Trends Mol Med. 21:212–222. 2015. View Article : Google Scholar : PubMed/NCBI
12	Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The hippo pathway and YAP/TAZ-TEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J Med Chem. 58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
13	Gibault F, Corvaisier M, Bailly F, Huet G, Melnyk P and Cotelle P: Non-photoinduced biological properties of verteporfin. Curr Med Chem. 23:1171–1184. 2016. View Article : Google Scholar : PubMed/NCBI
14	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
15	Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H and Roitberg AE: MMPBSA.py: An efficient program for end-state free energy calculations. J Chem Theory Comput. 8:3314–3321. 2012. View Article : Google Scholar : PubMed/NCBI
16	Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, et al: The protein data bank. Acta Crystallogr D Biol Crystallogr. 58((Pt 6 No 1)): 899–907. 2002. View Article : Google Scholar : PubMed/NCBI
17	Rostkowski M, Olsson MH, Søndergaard CR and Jensen JH: Graphical analysis of pH-dependent properties of proteins predicted using PROPKA. BMC Struct Biol. 11:62011. View Article : Google Scholar : PubMed/NCBI
18	Yu FX, Zhao B and Guan KL: Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
19	Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
20	Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK, et al: A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 19:106–119. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X and Li J: Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 108:478–487. 2017. View Article : Google Scholar : PubMed/NCBI
22	Dong L, Lin F, Wu W, Liu Y and Huang W: Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway. Int J Med Sci. 15:645–652. 2018. View Article : Google Scholar : PubMed/NCBI
23	Shi G and Wang H, Han H, Gan J and Wang H: Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition. Exp Ther Med. 16:2751–2755. 2018.PubMed/NCBI
24	Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
25	Moroishi T, Hansen CG and Guan KL: The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79. 2015. View Article : Google Scholar : PubMed/NCBI
26	Mesrouze Y, Meyerhofer M, Bokhovchuk F, Fontana P, Zimmermann C, Martin T, Delaunay C, Izaac A, Kallen J, Schmelzle T, et al: Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ. Protein Sci. 26:2399–2409. 2017. View Article : Google Scholar : PubMed/NCBI
27	Pobbati AV, Han X, Hung AW, Weiguang S, Huda N, Chen GY, Kang C, Chia CS, Luo X, Hong W, et al: Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure. 23:2076–2086. 2015. View Article : Google Scholar : PubMed/NCBI
28	Gibault F, Sturbaut M, Bailly F, Melnyk P and Cotelle P: Targeting transcriptional enhanced associate domains (TEADs). J Med Chem. 61:5057–5072. 2018. View Article : Google Scholar : PubMed/NCBI
29	Li Y, Liu S, Ng EY, Li R, Poulsen A, Hill J, Pobbati AV, Hung AW, Hong W, Keller TH and Kang C: Structural and ligand binding analysis of the YAP-binding domain of transcription factor TEAD4. Biochem J. 475:2043–2055. 2018. View Article : Google Scholar : PubMed/NCBI
30	Tian W, Yu J, Tomchick DR, Pan D and Luo X: Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci USA. 107:7293–7298. 2010. View Article : Google Scholar : PubMed/NCBI
31	Lin KC, Park HW and Guan KL: Regulation of the hippo pathway transcription factor TEAD. Trends Biochem Sci. 42:862–872. 2017. View Article : Google Scholar : PubMed/NCBI
32	Vlug EJ, Van De Ven RA, Vermeulen JF, Bult P, van Diest PJ and Derksen PW: Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr). 36:375–384. 2013. View Article : Google Scholar : PubMed/NCBI
33	Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et al: The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
34	Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, et al: XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 538:114–117. 2016. View Article : Google Scholar : PubMed/NCBI
35	Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reynies A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC and Jean D: Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res. 23:3191–3202. 2016. View Article : Google Scholar : PubMed/NCBI
36	Lin C, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C and LaBarge MA: Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol Biol Cell. 26:3946–3953. 2015. View Article : Google Scholar : PubMed/NCBI
37	Li Y, Wang S, Wei X, Zhang S, Song Z, Chen X and Zhang J: Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance. Cancer Sci. 110:561–567. 2019. View Article : Google Scholar : PubMed/NCBI
38	Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, et al: YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 35:1541–1543. 2016. View Article : Google Scholar : PubMed/NCBI
39	Li W, Cao Y, Xu J, Wang Y, Li W, Wang Q, Hu Z, Hao Y, Hu L, Sun Y, et al: YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer. J Exp Clin Cancer Res. 36:1442017. View Article : Google Scholar : PubMed/NCBI
40	Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD and Rowley DR: Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65:8887–8895. 2005. View Article : Google Scholar : PubMed/NCBI
41	Hutchenreuther J, Vincent KM, Carter DE, Postovit LM and Leask A: CCN2 expression by tumor stroma is required for melanoma metastasis. J Invest Dermatol. 135:2805–2813. 2015. View Article : Google Scholar : PubMed/NCBI
42	Li MH, Sanchez T, Pappalardo A, Lynch KR, Hla T and Ferrer F: Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res. 6:1649–1656. 2008.PubMed/NCBI
43	Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A and Takigawa M: Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res. 21:1045–1059. 2006. View Article : Google Scholar : PubMed/NCBI